trending Market Intelligence /marketintelligence/en/news-insights/trending/ye9UOWkogrHln2kDLTYfxQ2 content esgSubNav
In This List

Abbott's board approves $3B stock buyback

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Abbott's board approves $3B stock buyback

The board of Abbott Laboratories has approved a buyback for up to $3 billion worth of outstanding common shares.

The latest repurchase is in addition to an unused $795 million buyback program that was issued by the Abbott Park, Ill.-based medical-device maker's board in September 2014.

Abbott, which manufactures cardiovascular, diabetes and other devices, recently received U.S. Food and Drug Administration approval for the Architect Stat High Sensitivity Troponin-I blood test. The device helps detect a heart attack faster.